Discontinuation of CDK4/6 inhibitor Abemaciclib clinical trials

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

This study looks at whether some women with advanced breast cancer, already doing well on certain treatments, can safely stop one of their medicines (CDK4/6 inhibitors) and continue with other hormone therapy. The aim is to see if they can maintain control over their cancer without it.